Phiusion Labs

Phiusion Labs is a biotechnology company focused on developing a new class of protein-based therapeutics using its proprietary Phi-fusion platform. The company's technology is based on the work of Dr. Peter S. Kim and involves engineering fusion proteins that can potently inhibit viral entry by targeting conserved regions of viral spike proteins. Initially focused on COVID-19 and other respiratory viruses, Phiusion Labs aims to create broad-spectrum antivirals and expand its platform into oncology and other therapeutic areas. The company leverages advanced structural biology and protein design to address unmet needs in global health. It is currently advancing its lead candidates through pre-clinical development.